Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

By M. Wermke, D. Araujo, Manik Chatterjee, A. Tsimberidou, T. Holderried, A. Jazaeri, Ran Reshef, C. Bokemeyer, W. Alsdorf, K. Wetzko and 30 more. 2025

Subfields: Cancer Research, Immunology and Allergy, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “PRAME has emerged as a pan-cancer target, supported by systematic reviews [14] and on-going clinical trials investigating autologous T cell therapies in PRAME-positive advanced solid tumors [24].”